HNK20 antibody data

ORVX reported initial results of a Phase II safety and tolerance study of HNK20, given as a nose drop once daily, to prevent viral pneumonia caused by RSV in infants.

The double-blind, placebo-controlled study included 57 infants, under the age of 9 months at entry, with preexisting conditions including prematurity and chronic lung disease. Patients received either 2.5 mg/day of HNK20 or placebo. There were no adverse events and HNK20 was well-tolerated. ...